Pancreatic Cancer, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 36-5 - October 20, 2022
- Latest edition
- Editors: Matthew B. Yurgelun, Douglas A. Rubinson
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 8 6 5 5 - 7
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 8 6 5 6 - 4
In this issue of Hematology/Oncology Clinics, guest editors Drs. Matthew B. Yurgelun and Douglas A. Rubinson bring their considerable expertise to the topic of Pancreatic Cancer.… Read more
Purchase options
In this issue of Hematology/Oncology Clinics, guest editors Drs. Matthew B. Yurgelun and Douglas A. Rubinson bring their considerable expertise to the topic of Pancreatic Cancer. Top experts in the field cover key topics such as pancreatic adenocarcinoma: trends in epidemiology, risk factors, and outcomes; decision making regarding perioperative therapy in individuals with localized pancreatic adenocarcinoma; the evolving role of radiotherapy in the management of individuals with pancreatic adenocarcinoma; and more.
-
Contains 14 relevant, practice-oriented topics including diabetes, cachexia, sarcopenia, and metabolic factors in individuals with pancreatic adenocarcinoma; PARP inhibitors and other novel therapeutics in pancreatic adenocarcinoma; screening and surveillance for pancreatic adenocarcinoma in high-risk individuals; germline testing for individuals with pancreatic adenocarcinoma and novel genetic risk factors; and more.
-
Provides in-depth clinical reviews on pancreatic cancer, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Pancreatic Adenocarcinoma: Trends in Epidemiology, Risk Factors, and OutcomesThe Interplay Among Pancreatic Cancer, Cachexia, Body Composition, and DiabetesWhat Can We Learn About Pancreatic Adenocarcinoma from Imaging?Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk IndividualsGermline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk FactorsDecision-Making Regarding Perioperative Therapy in Individuals with Localized Pancreatic AdenocarcinomaNovel Considerations in Surgical Management of Individuals with Pancreatic AdenocarcinomaRadiotherapy for Pancreatic Adenocarcinoma: Recent Developments and Advances on the HorizonCytotoxic Chemotherapy in Advanced Pancreatic CancerPARPis and Other Novel, Targeted Therapeutics in Pancreatic AdenocarcinomaGenetics of Pancreatic Neuroendocrine TumorsPalliative and Supportive Care for Individuals with Pancreatic Adenocarcinoma
- Edition: 1
- Latest edition
- Volume: 36-5
- Published: October 20, 2022
- Language: English
MY
Matthew B. Yurgelun
Affiliations and expertise
Assistant Professor, Medicine, Harvard Medical School, Assistant Professor, Medical Oncology, Dana-Farber Cancer InstituteDR
Douglas A. Rubinson
Affiliations and expertise
Assistant Professor, Medicine, Dana-Farber Cancer Institute and Harvard Medical School